Purpose: Adding losartan (LOS) to FOLFIRINOX (FFX) chemotherapy followed by chemoradiation (CRT) resulted in 61% R0 surgical resection in our phase II trial in patients with locally advanced pancreatic cancer (LAPC). Here we identify potential mechanisms of benefit by assessing the effects of neoadjuvant LOS on the tumor microenvironment. Experimental Design: We performed a gene expression and immunofluorescence (IF) analysis using archived surgical samples from patients treated with LOS+FFX+CRT (NCT01821729), FFX+CRT (NCT01591733), or surgery upfront, without any neoadjuvant therapy. We also conducted a longitudinal analysis of multiple biomarkers in the plasma of treated patients. Results: In comparison with FFX+CRT, LOS+FFX+CRT downregulated immunosuppression and pro-invasion genes. Overall survival (OS) was associated with dendritic cell (DC) and antigen presentation genes for patients treated with FFX+CRT, and with immunosuppression and invasion genes or DC- and blood vessel–related genes for those treated with LOS+FFX+CRT. Furthermore, LOS induced specific changes in circulating levels of IL-8, sTie2, and TGF-β. IF revealed significantly less residual disease in lesions treated with LOS+FFX+CRT. Finally, patients with a complete/near complete pathologic response in the LOS+FFX+CRT–treated group had reduced CD4+FOXP3+ regulatory T cells (Tregs), fewer immunosuppressive FOXP3+ cancer cells (C-FOXP3), and increased CD8+ T cells in pancreatic ductal adenocarcinoma lesions. Conclusions: Adding LOS to FFX+CRT reduced pro-invasion and immunosuppression–related genes, which were associated with improved OS in patients with LAPC. Lesions from responders in the LOS+FFX+CRT–treated group had reduced Tregs, decreased C-FOXP3 and increased CD8+ T cells. These findings suggest that LOS may potentiate the benefit of FFX+CRT by reducing immunosuppression.
24 May 2025 in Journal for ImmunoTherapy of Cancer
Background Immune checkpoint blockers (ICBs) have revolutionized cancer therapy, yet they remain largely ineffective in treating pancreatic ductal adenocarcinoma (PDAC). Moreover, ICBs can cause severe immune-related adverse events (irAEs), including fatal cardiac toxicity. Finally, obesity is a risk factor in PDAC that may differentially modulate ICB efficacy in a malignancy-dependent manner. Methods We investigated the mechanisms underlying irAEs induced by dual ICB therapy and sought to identify strategies to mitigate them while improving ICB efficacy in the obese setting. To this end, we used a clinically relevant mouse model that integrated key features of human PDAC: (1) high-fat diet-induced obesity, (2) an orthotopic PDAC, and (3) a therapeutic regimen combining chemotherapy (FOLFIRINOX) with ICBs (α-programmed cell death protein-1 + α-cytotoxic T-lymphocyte associated protein-4 antibodies). Results Obese mice developed cardiac irAEs and had elevated serum interleukin (IL)-1β levels after chemoimmunotherapy. IL-1β blockade not only prevented myocarditis and reduced cardiac fibrosis but also enhanced the antitumor efficacy of the combination of chemotherapy plus dual ICB therapy and significantly improved the overall survival of PDAC-bearing obese mice. Conclusions Our findings provide the rationale and compelling data to test a Food and Drug Administration-approved anti-IL-1β antibody in combination with chemotherapy and dual ICB therapy in patients with pancreatic cancer with obesity.
Elastic fibers are key extracellular components, providing elasticity to blood vessels, lungs, skin, and bladder. Elastic fiber formation requires the accessory proteins fibulin‐4, fibulin‐5, and the long and short isoforms of the latent TGFβ binding protein‐4 (LTBP‐4L/S). We established two molecular axes, LTBP‐4L/fibulin‐4 and LTBP‐4S/fibulin‐5, defined similar and distinct functions, and determined the role of N‐linked glycans in this context. Glycoproteomic analysis identified the specific N‐linked glycans in these proteins. Biophysical analyses revealed that the N‐linked glycans of LTBP‐4L, but not fibulin‐4, were critical for fibulin‐4‐mediated conformational extension of LTBP‐4L, impacting its function and assembly. Biochemical and recombinant removal of N‐linked glycans from fibulin‐4 enhanced its interaction with tropoelastin and elastic fiber formation, indicating an inhibitory role for these N‐glycans. Fibulin‐5 strongly interacted with and robustly induced a conformational extension of LTBP‐4S, leading to enhanced binding to fibronectin, increased LTBP‐4S deposition, and doubling of elastic fiber formation. Loss of N‐linked glycans from fibulin‐5, but not LTBP‐4S, reduced their interaction by about 10‐fold and abolished the ability of fibulin‐5 to extend LTBP‐4S conformationally. The presence of fibulin‐5‐extended LTBP‐4S did not trigger tropoelastin aggregation in an in vitro assembly assay but boosted elastic fiber‐like assembly massively when fibulin‐4 and LTBP‐4L were additionally present, suggesting synergistic effects. N‐linked glycans in fibulin‐5 were essential in this process. The study uncovers novel mechanisms that regulate elastic fiber formation, including overlapping and distinct roles of the LTBP‐4L/fibulin‐4 and the LTBP‐4S/fibulin‐5 axes and the importance of N‐linked glycans of each of these proteins.